Vectors Research Management LLC Buys 901 Shares of Stryker Corporation (NYSE:SYK)

Vectors Research Management LLC raised its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 34.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,535 shares of the medical technology company's stock after purchasing an additional 901 shares during the quarter. Vectors Research Management LLC's holdings in Stryker were worth $1,316,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. Harbour Capital Advisors LLC increased its holdings in shares of Stryker by 71.8% during the first quarter. Harbour Capital Advisors LLC now owns 2,926 shares of the medical technology company's stock worth $1,077,000 after buying an additional 1,223 shares in the last quarter. Retirement Guys Formula LLC acquired a new position in shares of Stryker during the first quarter valued at $1,446,000. YHB Investment Advisors Inc. boosted its holdings in Stryker by 0.5% in the first quarter. YHB Investment Advisors Inc. now owns 47,531 shares of the medical technology company's stock valued at $17,693,000 after acquiring an additional 234 shares during the last quarter. Consolidated Portfolio Review Corp acquired a new stake in Stryker in the first quarter worth about $231,000. Finally, Legacy Advisors LLC raised its holdings in Stryker by 3.3% during the 1st quarter. Legacy Advisors LLC now owns 11,580 shares of the medical technology company's stock worth $4,311,000 after purchasing an additional 369 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on SYK shares. Needham & Company LLC restated a "buy" rating and issued a $442.00 price objective on shares of Stryker in a report on Friday, March 21st. Citigroup reiterated a "buy" rating and issued a $455.00 price objective (up previously from $443.00) on shares of Stryker in a report on Thursday, May 22nd. Roth Mkm raised their target price on Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Sanford C. Bernstein set a $450.00 price target on Stryker in a research note on Monday, May 5th. Finally, BTIG Research set a $403.00 price objective on shares of Stryker and gave the stock a "buy" rating in a research note on Monday, April 14th. Four analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $427.30.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director now owns 3,417,326 shares in the company, valued at $1,288,195,208.96. The trade was a 5.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 5.20% of the stock is owned by corporate insiders.

Stryker Price Performance

Stryker stock traded up $7.64 during trading hours on Tuesday, reaching $386.80. 1,746,007 shares of the stock were exchanged, compared to its average volume of 1,334,370. The stock has a 50 day moving average of $375.47 and a two-hundred day moving average of $375.11. The company has a current ratio of 1.64, a quick ratio of 1.00 and a debt-to-equity ratio of 0.69. Stryker Corporation has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a market cap of $147.64 billion, a P/E ratio of 52.27, a price-to-earnings-growth ratio of 2.83 and a beta of 0.91.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. The firm had revenue of $5.87 billion for the quarter, compared to analysts' expectations of $5.68 billion. Stryker had a net margin of 12.31% and a return on equity of 23.74%. The company's revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.50 earnings per share. Equities analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be issued a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.87%. Stryker's payout ratio is 45.41%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.